News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,153 Results
Type
Article (42249)
Company Profile (436)
Press Release (670468)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208706)
Career Advice (2021)
Deals (36002)
Drug Delivery (104)
Drug Development (83562)
Employer Resources (173)
FDA (16419)
Job Trends (15091)
News (352735)
Policy (33067)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50930)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16405)
Artificial intelligence (256)
Autoimmune disease (24)
Automation (15)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2138)
Cardiovascular disease (178)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (425)
Cervical cancer (19)
Clinical research (67632)
Collaboration (836)
Compensation (513)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2079)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87574)
Editorial (38)
Employer branding (21)
Employer resources (147)
Events (115445)
Executive appointments (711)
FDA (17620)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (753)
Gene editing (109)
Generative AI (20)
Gene therapy (311)
GLP-1 (737)
Government (4490)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (122)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (488)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (288)
MASH (65)
Medical device (13492)
Medtech (13497)
Mergers & acquisitions (19735)
Metabolic disorders (691)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1964)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2562)
Now hiring (38)
Obesity (376)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (224)
Patient recruitment (100)
Peanut (47)
People (58591)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29840)
Phase III (22072)
Pipeline (1140)
Policy (135)
Postmarket research (2601)
Preclinical (9068)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (395)
Real estate (6014)
Recruiting (66)
Regulatory (22664)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2220)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (22)
The Weekly (47)
United States (22577)
Vaccines (685)
Venture capitalists (38)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (108)
Last 7 days (510)
Last 30 days (2556)
Last 365 days (34031)
2025 (9436)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39167)
Australia (6524)
California (5911)
Canada (1949)
China (499)
Colorado (259)
Connecticut (275)
Delaware (137)
Europe (85579)
Florida (863)
Georgia (203)
Idaho (57)
Illinois (528)
India (25)
Indiana (303)
Iowa (10)
Japan (150)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (877)
Massachusetts (4512)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1691)
New Mexico (30)
New York (1672)
North Carolina (1003)
North Dakota (7)
Northern California (2562)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1317)
Puerto Rico (11)
Rhode Island (31)
South America (1110)
South Carolina (19)
South Dakota (1)
Southern California (2220)
Tennessee (99)
Texas (879)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,153 Results for "revance therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Crown Laboratories Completes Acquisition of Revance Therapeutics
February 7, 2025
·
3 min read
Press Releases
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
February 5, 2025
·
5 min read
Press Releases
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
February 6, 2025
·
4 min read
Mergers & acquisitions
Crown Laboratories to Buy Botox Rival Revance Therapeutics for $924M
The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.
August 13, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
Revance to Participate in Upcoming June 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
May 28, 2024
·
1 min read
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition.
May 9, 2024
·
11 min read
BioMidwest
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2024
Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units to 31 employees.
June 14, 2024
·
5 min read
Press Releases
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
January 21, 2025
·
10 min read
BioMidwest
Revance to Participate in Upcoming March 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
February 21, 2024
·
1 min read
Business
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 9, 2024
·
18 min read
1 of 71,316
Next
